Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials

Reference

• Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13–20.
   PubMed Web of Science ®Google Scholar
• Gersh BJ, Stone GW, White HD, et al. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA. 2005;293:979–986.
   PubMed Web of Science ®Google Scholar
• Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121–1135.
   PubMed Web of Science ®Google Scholar
• Ibanez B, Heusch G, Ovize M, et al. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 2015;65:1454–1471.
   PubMed Web of Science ®Google Scholar
• Heusch G. Treatment of myocardial ischemia/reperfusion injury by ischemic and pharmacological postconditioning. Compr Physiol. 2015;5:1123–1145.
   PubMed Web of Science ®Google Scholar
• Dokken BB, La Bonte LR, Davis-Gorman G, et al. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res. 2011;43:300–305.
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004;110:955–961.
   PubMed Web of Science ®Google Scholar
• Monami M, Dicembrini I, Nardini C, et al. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:38–47.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65–W94.
   PubMed Web of Science ®Google Scholar
• Higgins J, Green S. Cochrane handbook for systematic renews of interventions version 5.1.0. The Cochrane Collaboration. [updated 2011 Mar]. Available from: http://www.cochrane-handbook.org
   Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
   PubMed Web of Science ®Google Scholar
• Read PA, Hoole SP, White PA, et al. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc Interv. 2011;4:266–272.
   PubMed Web of Science ®Google Scholar
• Sokos GG, Bolukoglu H, German J, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007;100:824–829.
   PubMed Web of Science ®Google Scholar
• Chen WR, Shen XQ, Zhang Y, et al. Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine. 2016;52:516–526.
   PubMed Web of Science ®Google Scholar
• Kyhl K, Lonborg J, Vejlstrup N, et al. A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction. Euro Intervention. 2016;12:449–455.
   Google Scholar
• Roos ST, Timmers L, Biesbroek PS, et al. No benefit of additional treatment with exenatide in patients with an acute myocardial infarction. Int J Cardiol. 2016;220:809–814.
   PubMed Web of Science ®Google Scholar
• Chen WR, Hu SY, Chen YD, et al. Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2015;170:845–854.
   Google Scholar
• Woo JS, Kim W, Ha SJ, et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscl Throm Vas. 2013;33:2252–2260.
   Web of Science ®Google Scholar
• Lonborg J, Vejlstrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:1491–1499.
   PubMed Web of Science ®Google Scholar
• Chen WR, Chen YD, Tian F, et al. Effects of liraglutide on reperfusion injury in patients with st-segment-elevation myocardial infarction. Circ Cardiovasc Imaging. 2016;9.
   Web of Science ®Google Scholar
• Ritsinger V, Malmberg K, Martensson A, et al. Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial. Lancet Diabetes Endocrinol. 2014;2:627–633.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhou H, Wu W, et al. Liraglutide protects cardiac microvascular endothelial cells against hypoxia/reoxygenation injury through the suppression of the SR-Ca(2+)-XO-ROS axis via activation of the GLP-1R/PI3K/Akt/survivin pathways. Free Radic Biol Med. 2016;95:278–292.
   PubMed Web of Science ®Google Scholar
• Hattori Y, Jojima T, Tomizawa A, et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia. 2010;53:2256–2263.
   PubMed Web of Science ®Google Scholar
• Nishikage T, Nakai H, Mor-Avi V, et al. Quantitative assessment of left ventricular volume and ejection fraction using two-dimensional speckle tracking echocardiography. Eur J Echocardiogr. 2009;10:82–88.
   PubMed Web of Science ®Google Scholar
• Guo YK, Yang ZG, Ning G, et al. Sixty-four-slice multidetector computed tomography for preoperative evaluation of left ventricular function and mass in patients with mitral regurgitation: comparison with magnetic resonance imaging and echocardiography. Eur Radiol. 2009;19:2107–2116.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005;54:146–151.
   PubMed Web of Science ®Google Scholar
• Du J, Zhang L, Wang Z, et al. Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts. Am J Physiol Cell Physiol. 2016;310:C270–C283.
   PubMed Web of Science ®Google Scholar
• Oswald GA, Corcoran S, Yudkin JS. Prevalence and risks of hyperglycaemia and undiagnosed diabetes in patients with acute myocardial infarction. Lancet. 1984;1:1264–1267.
   PubMed Web of Science ®Google Scholar
• Marfella R, Siniscalchi M, Esposito K, et al. Effects of stress hyperglycemia on acute myocardial infarction: role of inflammatory immune process in functional cardiac outcome. Diabetes Care. 2003;26:3129–3135.
   PubMed Web of Science ®Google Scholar
• Zhao T, Parikh P, Bhashyam S, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006;317:1106–1113.
   PubMed Web of Science ®Google Scholar